As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan

Thrombosis and Haemostasis

Volumn 105, Issue 5, 2011, Pages 925-927

  Ichinose, Akitada ^a   Souri, Masayoshi ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 13 CONCENTRATE; BLOOD CLOTTING FACTOR 13 INHIBITOR; BLOOD CLOTTING INHIBITOR; CYCLOPHOSPHAMIDE; PREDNISOLONE; PROTHROMBIN; RITUXIMAB; TACROLIMUS; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ADULT; AGED; BLEEDING TENDENCY; BLOOD ANALYSIS; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BLOOD CLOTTING TEST; CLINICAL ARTICLE; COMORBIDITY; FEMALE; HEMOPHILIA; HUMAN; JAPAN; LETTER; MALE; MEDICAL LITERATURE; MORTALITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; FACTOR XIII; FACTOR XIII DEFICIENCY; FEMALE; HEMORRHAGE; HUMANS; IMMUNOSUPPRESSION; JAPAN; MALE; MIDDLE AGED;

EID: 79955776731     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-11-0724     Document Type: Letter

References (13)

1. Lorand L. Acquired inhibitors of fibrin stabilization: A class of hemorrhagic disorders of diverse origins. In: Anticoagulants, Physiologic, Pathologic and Pharmacologic. Boca Raton, FL: CRC Press; 1994: pp. 169-191.
2. Egbring R, Kröniger A, Seitz R. Erworbene Inhibitoren gegen Faktor XIII. Hämostaseologie 1996; 16: 174-179.
3. Teruya J, Kinoshita T, Yoshimura Y, et al. An inhibitor to factor XIII interacting with its activated catalytic subunit. Rinsho Ketsueki 1986; 27: 1680-1687.
4. Nakamura S, Kato A, Sakata Y, et al. Bleeding tendency caused by IgG inhibitor to factor XIII, treated successfully by cyclophosphamide. Br J Haematol 1988; 68: 313-319.
5. Lorand L, Velasco PT, Hill JM, et al. Intracranial hemorrhage in systemic lupus erythematosus associated with an autoantibody against actor XIII. Thromb Haemost 2002; 88: 919-923.
6. Nijenhuis AV, van Bergeijk L, Huijgens PC, et al. Acquired factor XIII deficiency due to an inhibitor: a case report and review of the literature. Haematologica 2004; 89: e46-e48.
7. Miesbach W. Rituximab in the treatment of factor XIII inhibitor possibly caused by Ciprofloxacin. Thromb Haemost 2005; 93: 1001-1003.
8. Lim W, Moffat K, Hayward CP. Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency. J Thromb Haemost 2004; 2: 1017-1019.
9. Ajzner E, Schlammadinger A, Kerényi A, et al. Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency. Blood 2009; 113: 723-725.
10. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981; 45: 200-203.
11. Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007; 109: 1870-1877.
12. Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993; 81: 1513-1520.
13. Ishida, F, Okubo K, Ito T, et al. Spontaneous regression of the inhibitor against the coagulation factor XIII A subunit in acquired factor XIII deficiency. Thromb Haemost 2010; 104: 1284-1285.